The adverse events associated with combination immunotherapy in cancers: Challenges and chances-Reference-Cited by-同舟云学术

The adverse events associated with combination immunotherapy in cancers: Challenges and chances

Published:2020-08-12 Issue:5 Volume:16 Page:
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Zhuo Minglei¹,Chi Yujia¹,Wang Ziping¹^ORCID

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Department of Thoracic Medical Oncology Peking University Cancer Hospital & Institute Beijing China

Funder

Beijing Municipal Science and Technology Commission

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13365

Reference33 articles.

1. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

3. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

4. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

5. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis;Nature Communications;2024-03-26

3. Therapeutic targeting of the pituitary tumor microenvironment;Pharmacology & Therapeutics;2023-10

4. Severe cardiac events induced by combination immunotherapy in patients with cancer: a meta-analysis;Archives of Medical Science;2023-08-20

5. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis;2023-05-16